Por favor, inténtelo con una nueva búsqueda
Amgen Inc. descubre, desarrolla, fabrica y suministra terapias humanas en todo el mundo. Los principales productos de la empresa incluyen Enbrel para tratar la psoriasis en placas, la artritis reumatoide y la artritis psoriásica; Otezla para el tratamiento de pacientes adultos con psoriasis en placas, artritis psoriásica y úlceras orales asociadas a la enfermedad de Behçet; Prolia para tratar a mujeres posmenopáusicas con osteoporosis; XGEVA para la prevención de acontecimientos relacionados con el esqueleto; Repatha, que reduce los riesgos de infarto de miocardio, ictus y revascularización coronaria; Nplate para el tratamiento de pacientes con trombocitopenia inmunitaria; KYPROLIS para el tratamiento de pacientes con mieloma múltiple en recaída o resistente al tratamiento; Aranesp para el tratamiento de un número de glóbulos rojos inferior al normal y de la anemia; EVENITY para el tratamiento de la osteoporosis posmenopáusica en hombres y mujeres; Vectibix para el tratamiento de pacientes con cáncer colorrectal metastásico RAS de tipo salvaje; BLINCYTO para el tratamiento de pacientes con leucemia linfoblástica aguda; TEPEZZA para el tratamiento de la enfermedad ocular tiroidea; y KRYSTEXXA para el tratamiento de la gota crónica refractaria. También comercializa otros productos, como Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA y PROCYSBI. La empresa atiende a proveedores de atención sanitaria, incluidos médicos o sus clínicas, centros de diálisis, hospitales y farmacias. Distribuye sus productos a través de distribuidores farmacéuticos mayoristas, así como de canales directos al consumidor. La empresa tiene acuerdos de colaboración con AstraZeneca plc para el desarrollo y la comercialización de TEZSPIRE; Novartis Pharma AG para el desarrollo y la comercialización de Aimovig; UCB para el desarrollo y la comercialización de EVENITY; Kyowa Kirin Co., Ltd. para el desarrollo y la comercialización de rocatinlimab; y BeiGene, Ltd. para la expansión y el desarrollo de productos oncológicos. Amgen Inc. se constituyó en 1980 y tiene su sede en Thousand Oaks, California.
Nombre | Edad | Desde | Título |
---|---|---|---|
Robert A. Bradway | 58 | 2007 | Chairman, CEO & President |
Robert A. Eckert | 69 | 2012 | Lead Independent Director |
Greg C. Garland | 66 | 2013 | Independent Director |
Tyler E. Jacks | 62 | 2012 | Independent Director |
Brian J. Druker | 68 | 2018 | Independent Director |
Ellen J. Kullman | 67 | 2016 | Independent Director |
David Baltimore | 85 | 1999 | Co-Chair of Scientific Advisory Board |
Wanda M. Austin | 69 | 2017 | Independent Director |
Amy E. Miles | 56 | 2020 | Independent Director |
S. Omar Ishrak | 67 | 2021 | Independent Director |
Diane J. Mathis | - | - | Member of Scientific Advisory Board of Inflammation |
Ronald D. Sugar | 74 | 2010 | Independent Director |
R. Sanders Williams | 74 | 2014 | Independent Director |
Alexander Marson | - | 2022 | Member of Scientific Advisory Board of Inflammation |
Arlene Sharpe | - | 2022 | Member of Scientific Advisory Board of Inflammation |
Charles M. Holley | 66 | 2017 | Independent Director |
Lillian L. Siu | - | 2022 | Member of Scientific Advisory Board of Oncology |
S. Gail Eckhardt | - | 2022 | Member of Scientific Advisory Board of Oncology |
Richard O. Hynes | - | - | Member of Scientific Advisory Board of Research Trends & Emerging Technologies |
Maria T. Abreu | - | 2022 | Member of Scientific Advisory Board of Inflammation |
Michael V. Drake | 72 | 2022 | Independent Director |
Emma Guttman-Yassky | - | 2022 | Member of Scientific Advisory Board of Inflammation |
Meilan Han | - | 2022 | Member of Scientific Advisory Board of Inflammation |
Dirk Jäger | - | - | Member of Scientific Advisory Board of Oncology |
Robert S. Negrin | - | - | Member of Scientific Advisory Board of Oncology |
Daniel P. Kelly | - | - | Member of Scientific Advisory Board of Cardiovascular & Metabolic |
Robert Tjian | 74 | - | Member of Scientific Advisory Board Member of Research Trends & Emerging Technologies |
Siwen Hu-Lieskovan | - | - | Member of Scientific Advisory Board of Oncology |
Frank P. McCormick | 73 | - | Member of Scientific Advisory Board of Research Trends & Emerging Technologies |
Ronald M. Evans | 74 | - | Member of Scientific Advisory Board of Research Trends & Emerging Technologies |
John Kuriyan | - | - | Member of Scientific Advisory Board of Research Trends & Emerging Technologies |
Jeffery D. Molkentin | - | - | Member of Scientific Advisory Board of Cardiovascular & Metabolic |
George Georgiou | 64 | 2023 | Member of Scientific Advisory Board of Research Trends & Emerging Technologies |
David Alan Kass | - | - | Member of Scientific Advisory Board of Cardiovascular & Metabolic |
E. Dale Abel | - | - | Member of Scientific Advisory Board of Cardiovascular & Metabolic |
Elizabeth McNally | - | - | Member of Scientific Advisory Board of Cardiovascular & Metabolic |
Jonathan S. Weissman | - | - | Member of Scientific Advisory Board of Research Trends & Emerging Technologies |
Drew Mark Pardoll | - | - | Member of Scientific Advisory Board of Oncology |
Marlene Rabinovitch | - | - | Member of Scientific Advisory Board of Cardiovascular & Metabolic |
Dean Sheppard | - | 2022 | Member of Scientific Advisory Board of Inflammation |
Alexander Rudensky | - | 2022 | Member of Scientific Advisory Board of Inflammation |
Antoni Ribas | - | - | Member of Scientific Advisory Board of Oncology |
Benoit Van den Eynde | - | - | Member of Scientific Advisory Board of Oncology |
David J. Anderson | - | - | Member of Scientific Advisory Board of Research Trends & Emerging Technologies |
Peter Libby | 76 | - | Member of Scientific Advisory Board of Cardiovascular & Metabolic |
Ruslan Medzhitov | - | - | Member of Scientific Advisory Board of Research Trends & Emerging Technologies |
Daniel Joshua Drucker | - | - | Member of Scientific Advisory Board of Cardiovascular & Metabolic |
Charles Elliott Sigal | 72 | - | Co-Chair of the Scientific Advisory Board |
Thomas Quertermous | 72 | - | Member of Scientific Advisory Board of Cardiovascular & Metabolic |
¿Está seguro de que desea bloquear a %USER_NAME%?
Al hacerlo, ni usted ni %USER_NAME% podrán ver las publicaciones del otro en Investing.com.
Se ha agregado correctamente a %USER_NAME% a su lista de usuarios bloqueados
Acaba de desbloquear a esta persona; tiene que esperar 48 horas para poder bloquearla de nuevo.
Díganos qué piensa de este comentario
Gracias
Su denuncia será examinada por nuestros moderadores